ANIXA BIOSCIENCES, INC. Revenue
ANIXA BIOSCIENCES, INC. (ANIX) reported Revenue of $210.00 thousand for the 12-month period ending 2024-10-31, per its 10-K filed 2025-01-10.
Financial Statements › Income Statement › Revenue
us-gaap:Revenues · last filed 2025-01-10
- ANIXA BIOSCIENCES, INC. revenues for the quarter ending 2023-10-31 was $0.00.
- ANIXA BIOSCIENCES, INC. revenues for the quarter ending 2023-07-31 was $0.00.
- ANIXA BIOSCIENCES, INC. revenues for the quarter ending 2023-04-30 was $210.00K.
- ANIXA BIOSCIENCES, INC. revenues for the quarter ending 2023-01-31 was $0.00, a 100.00% decline year-over-year.
- ANIXA BIOSCIENCES, INC. revenues for fiscal 2024 was $210.00K, a 0.00% change from fiscal 2023.
- ANIXA BIOSCIENCES, INC. revenues for fiscal 2023 was $210.00K.
- ANIXA BIOSCIENCES, INC. revenues for fiscal 2021 was $512.00K.
- ANIXA BIOSCIENCES, INC. revenues for fiscal 2019 was $250.00K, a 77.53% decline from fiscal 2018.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month | Revenues 12 month as first filed |
|---|---|---|---|---|---|
| 2024-10-31 | $210.00K 10-K · filed 2025-01-10 | ||||
| 2024-04-30 | $210.00K 10-Q · filed 2024-06-04 | ||||
| 2023-10-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-01-16 | $0.00 derived: sum of 2 quarters · filed 2024-01-16 | $210.00K derived: sum of 3 quarters · filed 2024-01-16 | $210.00K 10-K · filed 2024-01-16 | |
| 2023-07-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-09-06 | $210.00K derived: sum of 2 quarters · filed 2023-09-06 | $210.00K 10-Q · filed 2023-09-06 | ||
| 2023-04-30 | $210.00K 10-Q · filed 2023-06-14 | $210.00K 10-Q · filed 2023-06-14 | |||
| 2023-01-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2024-01-16 | ||||
| 2022-04-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-06-10 | $513.00K 10-Q · filed 2022-06-10 | $512.00K derived: sum of 3 quarters · filed 2023-01-04 | ||
| 2022-01-31 | $513.00K 10-Q · filed 2022-03-11 | $512.00K derived: sum of 2 quarters · filed 2023-01-04 | |||
| 2021-10-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-01-04 | $512.00K 10-K · filed 2023-01-04 | $512.50K 10-K · filed 2022-01-04 | ||
| 2021-07-31 | $513.00K 10-Q · filed 2022-09-09 | ||||
| 2021-01-31 | $512.50K 10-Q · filed 2021-03-11 | ||||
| 2019-10-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-01-07 | $0.00 derived: sum of 2 quarters · filed 2021-01-07 | $250.00K derived: sum of 3 quarters · filed 2021-01-07 | $250.00K 10-K · filed 2021-01-07 | |
| 2019-07-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-09-06 | $250.00K derived: sum of 2 quarters · filed 2020-06-09 | $250.00K 10-Q · filed 2019-09-06 | ||
| 2019-04-30 | $250.00K 10-Q · filed 2020-06-09 | $250.00K 10-Q · filed 2020-06-09 | |||
| 2018-10-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-01-09 | $362.50K derived: sum of 2 quarters · filed 2020-01-09 | $1.11M derived: sum of 3 quarters · filed 2020-01-09 | $1.11M 10-K · filed 2020-01-09 | |
| 2018-07-31 | $362.50K 10-Q · filed 2019-09-06 | $1.11M derived: sum of 2 quarters · filed 2019-09-06 | $1.11M 10-Q · filed 2019-09-06 | ||
| 2018-04-30 | $750.00K 10-Q · filed 2019-06-12 | $750.00K 10-Q · filed 2019-06-12 | |||
| 2017-10-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-01-11 | $362.50K derived: sum of 2 quarters · filed 2019-01-11 | $362.50K 10-K · filed 2019-01-11 | ||
| 2017-07-31 | $362.50K 10-Q · filed 2018-09-07 | $362.50K 10-Q · filed 2018-09-07 | |||
| 2016-10-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-01-09 | $300.00K derived: sum of 2 quarters · filed 2018-01-09 | $300.00K 10-K · filed 2018-01-09 | ||
| 2016-07-31 | $100.00K 10-Q · filed 2017-09-08 | $100.00K 10-Q · filed 2017-09-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Lexaria Bioscience Corp. (LEXX) | $0.084B | -1.92 |